A Study of BGM0504 in Early T2DM With Obesity

What Was Tested

This registered phase 3 trial tested Semaglutide.

This trial is conducted in China.

It had two arms (groups): one (experimental) and one (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 372 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: ○ Have been diagnosed with type 2 diabetes mellitus (T2DM)， disease duration ≤5 years, treatment naïve with ≥8 weeks diet/exercise, or off antidiabetic therapy ≥8 weeks prior to screening. If hypertensive: SBP \<180 mmHg and DBP \<110 mmHg at enrollment, on stable (≥2 weeks) ≤2 antihypertensives, or no medication with diet/exercise ≥4 weeks.

The full record lists 6 inclusion and 11 exclusion criteria; among the exclusions: ● previous diagnosis of type 1 diabetes, special type diabetes or gestational diabetes; prior use of antidiabetics or systemic glucocorticoids within 8 weeks, prior glp-1/gip/gcg receptor agonists with intolerance/poor response, or weight-loss drugs within 3 months; history of acute/chronic pancreatitis.

How the Study Was Run

Design: randomized, parallel-group and open-label.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2026-09-17 with completion listed for 2028-09-30.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 16 secondary outcomes, for example Proportion of Participants Achieving Diabetes Remission, Proportion of Participants Achieving Glycemic and Weight Targets at 12 Weeks Off Treatment, Change from Baseline in HbA1c, Change from Baseline in Fasting Plasma Glucose (FPG), Change from Baseline in 2-Hour Postprandial Glucose and Change from Baseline in Body Weight.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 372 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.